Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma

Genes Chromosomes and Cancer

Volumn 52, Issue 10, 2013, Pages 912-919

  Ortiz Cuaran, Sandra ^a   Cox, David ^b   Villar, Stéphanie ^a   Friesen, Marlin D ^c   Durand, Geoffroy ^a   Chabrier, Amélie ^a   Khuhaprema, Thiravud ^d   Sangrajrang, Suleeporn ^d   Ognjanovic, Simona ^e   Groopman, John D ^c   Hainaut, Pierre ^a,f   Le Calvez Kelm, Florence ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (Thailand)

^e UNIVERSITY OF MINNESOTA   (United States)

^f INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; GENOMIC DNA; PROTEIN P53; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; INTRON; LIVER CELL CARCINOMA; MALE; MUTAGENESIS; MUTATION RATE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; TUMOR SUPPRESSOR GENE;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883052630     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22086     Document Type: Article

References (25)

1. Batista LF, Pech MF, Zhong FL, Nguyen HN, Xie KT, Zaug AJ, Crary SM, Choi J, Sebastiano V, Cherry A, Giri N, Wernig M, Alter BP, Cech TR, Savage SA, Reijo Pera RA, Artandi SE. 2011. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474:399-402.
2. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. 2009. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology: 137:1127-1137.
3. Dumont P, Leu JI, Della PA, III, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
4. Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, Naqvi A, Frank AK, Rosenwaks Z, Murphy ME, Levine AJ, Hu W. 2011. Regulation of female reproduction by p53 and its family members. FASEB J 25:2245-2255.
5. Galy O, Chemin I, Le RE, Villar S, Le Calvez-Kelm F, Lereau M, Gouas D, Vieco B, Suarez I, Navas MC, Chevallier M, Norder H, Srivatanakul P, Karalak A, Sangrajrang S, Trepo C, Hainaut P. 2011. Mutations in TP53 and CTNNB1 in relation to Hepatitis B and C infections in hepatocellular carcinomas from Thailand. Hepat Res Treat 2011:697162.
6. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugieres L, Vargas FR, Brentani RR, shton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI. 2010. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 31:143-150.
7. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. 2004. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954-1956.
8. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. 2010. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol 2: a001032.
9. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L. 2010. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: A meta-analysis. Carcinogenesis 31:643-647.
10. Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, Rebbeck TR, Rosenwaks Z, Levine AJ, Hu W. 2009. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci USA 106:9761-9766.
11. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, Mendy M, Hollstein MC, Montesano R, Groopman JD, Hainaut P, Friesen MD. 2005. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. Cancer Epidemiol Biomarkers Prev 14:2956-2962.
12. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M. 2009. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33:462-471.
13. Mahmoudi S, Henriksson S, Weibrecht I, Smith S, Soderberg O, Stromblad S, Wiman KG, Farnebo M. 2010. WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. PLoS Biol 8:e1000521.
14. Marcel V, Tran PL, Sagne C, Martel-Planche G, Vaslin L, Teulade-Fichou MP, Hall J, Mergny JL, Hainaut P, Van DE. 2011. G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis 32:271-278.
15. Ortiz-Cuaran S, Villar S, Gouas D, Ferro G, Plymoth A, Khuhaprema T, Kalalak A, Sangranjang S, Friesen M, Groopman JD, Hainaut P. 2013. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Lett 331:46-51.
16. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. 2007. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165.
17. Pim D, Banks L. 2004. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199.
18. Reisman D, Greenberg M, Rotter V. 1988. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci USA 85:5146-5150.
19. Reisman D, Balint E, Loging WT, Rotter V, Almon E. 1996. A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. Genomics 38:364-370.
20. Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. 2013. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): Geographic and tumor-specific effects. Cell Death Dis 14: e492.
21. Salvioli S, Bonafe M, Barbi C, Storci G, Trapassi C, Tocco F, Gravina S, Rossi M, Tiberi L, Mondello C, Monti D, Franceschi C. 2005. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4:1264-1271.
22. Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, Peng Y, Qi XB, Shou WH, Ma RL, Li Y, Su B, Lu X. 2009. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 84:534-541.
23. Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van der SM, Whittle H, Friesen MD, Groopman JD, Hainaut P. 2011. Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and Hepatitis B virus infection. Environ Health Perspect 119:1635-1640.
24. Villar S, Ortiz-Cuaran S, bedi-Ardekani B, Gouas D, Nogueira da CA, Plymoth A, Khuhaprema T, Kalalak A, Sangrajrang S, Friesen MD, Groopman JD, Hainaut P. 2012. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: Association with tumors developing in the absence of liver cirrhosis. PLoS One 7: e37707.
25. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: Cancer implications. Nat Rev Cancer 9:95-107.